Strategic Pharmacovigilance Checklist for Biosimilar Safety in 2025
The rise of biosimilars has reshaped modern medicine by offering affordable alternatives to biologics. But with increased adoption comes the critical responsibility of ensuring patient safety. In 2025, regulators, manufacturers, and healthcare providers must align on strong pharmacovigilance strategies to monitor and manage biosimilar safety effectively. This checklist highlights the essential areas to prioritize.